US OptionsDetailed Quotes
INMB241115C7500
- 0.10
- +0.05+100.00%
15min DelayTrading Nov 4 12:18 ET
0.10High0.10Low
0.10Open0.05Pre Close4 Volume183 Open Interest7.50Strike Price40.00Turnover99.99%IV22.68%PremiumNov 15, 2024Expiry Date0.00Intrinsic Value100Multiplier11DDays to Expiry0.10Extrinsic Value100Contract SizeAmericanOptions Type0.1465Delta0.2142Gamma82.60Leverage Ratio-0.0111Theta0.0003Rho12.10Eff Leverage0.0025Vega
INmune Bio Stock Discussion
1 MINUTE AGO, 3:03 PM EDT
VIA GLOBENEWSWIRE
INMB
SHARE
Data from Animal Model Study Demonstrate XPro™ converts microglia from a demyelinating cell to a remyelinating cell
Multi-year study published has implications for many CNS diseases including Alzheimer's
INmune Bio Inc. Announces Publication in Cell Reports Demonstrating XPro™ Promotes Remyelination
INmune Bio (NASDAQ: INMB) announces publication in Cell Reports demonstrating XPro™'s ability to promote remyelination in demyelinating disease animal models. The study, led by Dr. Leslie Probert at Hellenic Pasteur Institute, shows that XPro1595 converts microglia from damaging to reparative cells by blocking soluble TNF. This research has implications for treating various ...
• $SpringWorks Therapeutics (SWTX.US)$ +19.2% (Nirogacestat Achieved Primary and All Key Secondary Endpoints in Phase3DeFi Trial )
• $Roivant Sciences (ROIV.US)$ +7.1% (FDA has approved VTAMA (tapinarof) cream)
• $Ocugen (OCGN.US)$ +5.9% (announces that it is diversifying its innovative pipeline by introducing a Phase 3 cell therapy platform technology called Ne?Cart)
• $Champion Homes (SKY.US)$ +4.4% (In reaction to earnings）
• $NetEase (NTES.US)$ +4.1% (In...
No comment yet